tiprankstipranks
Innovent Biologics (MX:1801N)
:1801N
Mexico Market
1801N
Innovent Biologics
RESEARCH TOOLSreports

Innovent Biologics (1801N) Income Statement

1 Followers

Innovent Biologics Income Statement

Last quarter (Q2 2026), Innovent Biologics's total revenue was ¥8.50B, an increase of 115.04% from the same quarter last year. In Q2, Innovent Biologics's net income was ¥1.24B. See Innovent Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
¥ 13.04B¥ 9.42B¥ 6.21B¥ 4.56B¥ 4.27B
Gross Profit
¥ 10.00B¥ 7.91B¥ 4.40B¥ 3.63B¥ 3.70B
Operating Expenses
¥ 9.26B¥ 7.65B¥ 6.08B¥ 6.21B¥ 5.75B
Depreciation and Amortization
¥ 576.53M¥ 275.60M¥ 385.10M¥ 319.42M¥ 204.75M
EBITDA
¥ 1.31B¥ -480.28M¥ -660.68M¥ -1.75B¥ -2.37B
Operating Income
¥ 733.62M¥ -755.87M¥ -1.68B¥ -3.12B¥ -2.70B
Other Income/Expenses
¥ 105.30M¥ -336.74M¥ 534.89M¥ 952.38M¥ 61.63M
Pretax Income
¥ 838.92M¥ -78.62M¥ -1.14B¥ -2.17B¥ -2.64B
Net Income
¥ 813.57M¥ -94.63M¥ -1.03B¥ -2.18B¥ -2.73B
Per Share Metrics
Basic EPS
¥ 0.48¥ -0.06¥ -0.66¥ -1.46¥ -1.88
Diluted EPS
¥ 0.47¥ -0.06¥ -0.66¥ -1.46¥ -1.88
Weighted Average Shares Outstanding
 1.73B 1.63B 1.56B 1.49B 1.45B
Weighted Average Shares Outstanding (Diluted)
 1.74B 1.63B 1.56B 1.49B 1.46B
Currency in CNY

Innovent Biologics Earnings and Revenue History